Anxiolytics, adrenergic agents, and naltrexone

Objective: To review extant data on the efficacy and safety of anxiolytic m edications (benzodiazepines, buspirone and other serotonin 1A agonists), ad renergic agents (P-blockers and alpha(2)-adrenergic agonists clonidine and guanfacine), and the opiate antagonist naltrexone that have been used to tr eat various psychopathologies in children and adolescents. To identify crit ical gaps in our current knowledge about these agents and needs for further research. Method: All available controlled trials of these medications in children and adolescents published in English through 1997 were reviewed. I n addition, selected uncontrolled studies are included. Results: The major finding, that there are virtually no controlled data that support the effic acy of most of these drugs for the treatment of psychiatric disorders in ch ildren and adolescents, is both surprising and unfortunate. For some drugs, e.g., buspirone and guanfacine, this is because no controlled studies have been carried out in children and/or adolescents. For other drugs, e.g., cl onidine and naltrexone, most of the placebo-controlled studies have failed to demonstrate efficacy Conclusions: The strongest recommendations for cont rolled studies of safety and efficacy in children and adolescents can be gi ven for the following drugs: benzodiazepines for acute anxiety; buspirone l and newer serotonin IA agonists as they become available) for anxiety and d epression; P-blockers for aggressive dyscontrol; guanfacine for attention-d eficit/hyperactivity disorder; and naltrexone for hyperactivity, inattentio n, and aggression in autistic disorder.